Indaptus Therapeutics Inc 2026年季度报告

FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40652 INDAPTUS THERAPEUTICS, INC. Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2)has been subject to such filing requirements for the past 90 days. YES☒NO☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrantwas required to submit such files). YES☒NO☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES☐NO☒ The number of shares of the Registrant’s common stock outstanding as of May 15, 2026 was 113,242,324. TABLE OF CONTENTS Page CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND SUMMARY RISK FACTORSiiPART I. FINANCIAL INFORMATIONF-1Item 1.Financial StatementsF-1Unaudited Condensed Consolidated Balance SheetsF-1Unaudited Condensed Consolidated Statements of Operations and Comprehensive LossF-2Unaudited Condensed Consolidated Statements of Stockholders’ EquityF-3Unaudited Condensed Consolidated Statements of Cash FlowsF-4Notes to Unaudited Condensed Consolidated Financial StatementsF-5Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations1Item 3.Quantitative and Qualitative Disclosures about Market Risk5Item 4.Controls and Procedures5PART II. OTHER INFORMATION6Item 1.Legal Proceedings6Item 1A.Risk Factors6Item 2.Unregistered Sales of Equity Securities and Use of Proceeds6Item 3.Defaults Upon Senior Securities6Item 4.Mine Safety Disclosures6Item 5.Other Information6Item 6.Exhibits6i CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, or Quarterly Report, contains, and management may make, certain forward-looking statements within themeaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in thisQuarterly Report are forward-looking statements. In some cases, forward-looking statements can be identified by the use of terms such as“believe,” “expect,” “intend,” “plan,” “may,” “should,” “anticipate,” “could,” “might,” “seek,” “target,” “will,” “project,” “forecast,”“continue” or their negatives or variations of these words or other comparable words. These statements include, without limitation, ourstatements about: our product candidates’ development, including the timing and design of the Phase 1 clinical trial of Decoy20 and ourcombination study; our expectations regarding the recommended Phase 2 dose for subsequent multi-dosing and combination studies and relatedtiming; the anticipated effects of our product candidates; our plans to develop and commercialize our product candidates; the market potentialand treatment potential of our product candidates, including Decoy20; our commercialization, marketing and manufacturing capabilities andstrategy; our expectations about the willingness of healthcare professionals to use our product candidates; our general business strategy and theplans and objectives of management for future operations; our research and development activities and costs; our future results of operationsand condition; the sufficiency of our cash and cash equivalents to fund our ongoing activities and our ability to continue as a going concern;and the impact of current macroeconomic conditions on our operations, ability to access capital, and liquidity. The forward-looking statements in this Quarterly Report are only predictions and are based largely on our current expectations and projectionsabout future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the